about
Identification of therapeutic targets applicable to clinical strategies in ovarian cancerCharacterization of ovarian cancer cell lines as in vivo models for preclinical studies.Clinical trials in gynecologic oncology: Past, present, and future.IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancerItaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumorsProduction of a cellular product consisting of monocytes stimulated with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for human use
P50
Q28829029-36C54E6A-6CE5-4F68-AB13-42A6ED4E2BEAQ38767850-3441D2B2-1B05-4F03-A116-C272A87FF3E9Q47796770-786BDB1D-0102-4FC5-AD7C-2674719EFBAEQ55247109-C659E001-A039-4263-AE50-B6D00275402EQ56517336-3A1D4181-66EC-4087-90D6-23DE9C475F10Q63409314-F6CABB20-E935-4DD7-A44D-E52D582DD4EBQ64094101-FF3E606B-4CDA-448E-A334-35A5C68650AE
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christina M Annunziata
@ast
Christina M Annunziata
@en
Christina M Annunziata
@es
Christina M Annunziata
@nl
type
label
Christina M Annunziata
@ast
Christina M Annunziata
@en
Christina M Annunziata
@es
Christina M Annunziata
@nl
prefLabel
Christina M Annunziata
@ast
Christina M Annunziata
@en
Christina M Annunziata
@es
Christina M Annunziata
@nl
P106
P21
P31
P3762
P496
0000-0003-2033-6532